Anfarm

What Anfarm does

ANFARM HELLAS S.A. is a privately held Greek pharmaceutical manufacturer operating since 1967 with EU GMP certification from Greek Health Authorities and accreditation from multiple National Health Authorities worldwide. The company specializes in four product categories: lyophilized products (with stated annual capacity of 40 million vials), β-lactam sterile powders and oral solid dosage forms (manufactured in a dedicated isolated unit), large and small volume liquid injectable pharmaceuticals, and conventional non-sterile oral solid and liquid dosage forms. It holds ISO 9001 certification since 2008 and operates a pharmacovigilance system compliant with EU Regulation (EC) No 726/2004, Directive 2001/83/EC, and Volume 9A, including registration with EUDRAVIGILANCE (EVWEB) and MedDRA. From facilities in Kifissia (headquarters and R&D center) and Schimatari, Viotia (manufacturing plant and logistics center), ANFARM serves multinational pharmaceutical companies seeking manufacturing partners for generic products.

The company monetizes through three distinct revenue streams: (1) generic pharmaceutical manufacturing and sale of β-lactams, lyophilized products, and liquid injectables; (2) licensing out of lyophilized products, cephalosporins, carbapenems, and other sterile and non-sterile products to international markets; and (3) technology transfer and contract manufacturing services delivered through the R&D Formulation Development and Analytical Development departments. Products are commercially available across Europe, Canada, South Africa, and emerging generic markets in MENA, LATAM, and APAC. Distribution is entirely B2B enterprise — direct exports, licensing agreements, and third-party manufacturing arrangements — with no consumer-facing channel. The go-to-market is operated through a dedicated Business Development & Licensing department handling inbound inquiries for licensing, technology transfer, and contract manufacturing.

R&D is positioned as both an internal pipeline engine (developing branded generic products that add value to ANFARM's portfolio) and an external service offering (formulation and analytical development supporting third-party technology transfers). The company has participated in Greece 2.0 NextGeneration EU funded projects (TACL1-0480193 and TACL3-0561674), indicating ongoing capacity and capability investment at the Schimatari site. Operating as ANFARM HELLAS S.A., the company is privately held with no disclosed parent, institutional investors, or venture capital backing.

Name

Anfarm

Legal name

ANFARM HELLAS S.A.

Website

https://anfarm.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Short description

ANFARM HELLAS S.A. is a Greek EU GMP-certified pharmaceutical manufacturer producing lyophilized products (40 million vials annually), β-lactams, liquid injectables, and oral generics for multinational pharma firms via licensing, direct exports, and contract manufacturing across Europe, Canada, MENA, LATAM, and APAC.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Sterile injectable manufacturing
• Lyophilized pharmaceuticals
• Beta-lactam manufacturing
• Contract pharmaceutical manufacturing
• Technology transfer services

Headquarters

HQ city

Kifissia

HQ country

Greece

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Generic Pharmaceuticals Manufacturing: Manufacturing and sale of generic pharmaceutical products including β-lactams, lyophilized products, and liquid injectable pharmaceuticals.
2. Licensing Out: Licensing agreements for lyophilized products, cephalosporins, carbapenems and other sterile and non-sterile products to international markets.
3. Technology Transfer & Contract Manufacturing: Third-party technology transfer and contract manufacturing services including formulation and analytical development.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels1 record

Core offering

ANFARM HELLAS S.A. is an EU GMP-certified pharmaceutical manufacturer based in Greece that produces lyophilized products, β-lactam sterile powders, oral solid dosage forms, and large and small volume liquid injectables at its manufacturing plant in Schimatari. The company also provides technology transfer services, formulation and analytical development, and contract manufacturing for third parties, and operates a global distribution network through licensing agreements and direct exports to Europe, Canada, South Africa, and emerging generic markets in MENA, LATAM, and APAC.

Product overview

ANFARM HELLAS S.A. is an EU GMP Pharmaceuticals manufacturer offering a comprehensive portfolio of sterile and non-sterile pharmaceutical products. The core product lines include lyophilized products (40 million vials annually), β-lactam sterile powders, oral solid dosage forms, liquid injectable pharmaceuticals (large and small volume), and conventional non-sterile oral solid and liquid dosage forms. The company provides associated services including technology transfer and contract manufacturing, as well as a comprehensive pharmacovigilance system compliant with EU directives.

Differentiator

Problem solved

Functional benefit

Products and services

• Lyophilized Products Lyophilized (freeze-dried) pharmaceutical products manufactured at industrial scale for multinational pharmaceutical customers, including products commercially available or under development.
• β-Lactam Sterile Powders and Oral Solid Dosage Forms Dedicated β-lactam sterile powders and oral solid dosage forms manufactured in a separate dedicated unit, covering cephalosporins, carbapenems, and related antibiotics for third-party partners.
• Liquid Injectable Pharmaceuticals Large and small volume liquid injectable sterile pharmaceutical products manufactured under EU GMP for multinational pharmaceutical customers and licensing partners.
• Oral Solid and Liquid Dosage Forms Conventional non-sterile pharmaceutical products including oral solid and oral liquid dosage forms manufactured for multinational customers and licensing partners.
• Technology Transfer Services Technology transfer services for third-party products executed through formulation and analytical development activities at ANFARM's R&D department, supporting contract manufacturing and licensing partnerships.
• Pharmacovigilance Services EU-compliant pharmacovigilance system and reporting services performed via EUDRAVIGILANCE (EVWEB) and MedDRA, supporting safety monitoring for ANFARM's licensed and contract-manufactured pharmaceutical products.

Quantifiable outcome

• 40 million vials of lyophilized products manufactured annually
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Aenova: European-based CDMO with broad solid dosage, sterile, and semi-solid manufacturing capabilities serving generic and pharmaceutical partners — directly comparable to ANFARM's CDMO/contract manufacturing model and European geographic footprint.
• Recipharm: European CDMO providing contract manufacturing of sterile and oral solid dosage forms to pharmaceutical companies — comparable CDMO model, multiple dosage form offerings, and European manufacturing presence.
• Polpharma: Polish generic pharmaceutical manufacturer with broad portfolio including sterile injectables and oral solids — comparable European-based generic manufacturer with similar dosage form capabilities and emerging market exports.
• KRKA: Slovenian generic pharmaceutical manufacturer with strong European and emerging market presence — comparable as a regional generic drug manufacturer with export-oriented business model and focus on affordable generics.
• CordenPharma: Full-service CDMO with sterile injectables, lyophilization, and oral solid dose capabilities serving global pharma — directly comparable in service mix (lyophilization, sterile, oral solids) and B2B contract manufacturing model.
• Vetter Pharma: Specialty CDMO focused on aseptic filling, lyophilization, and sterile injectable manufacturing for global pharma — highly comparable in lyophilization-as-core-capability and multinational pharma customer base.
• Hovione: Specialized CDMO with deep expertise in lyophilization, sterile injectables, and complex formulations serving global pharma — directly comparable in lyophilization scale and sterile injectable capabilities central to ANFARM's value proposition.
• Fareva: European CDMO offering sterile injectables, lyophilization, and oral dosage forms to multinational pharmaceutical clients — comparable in scope of sterile manufacturing services and European CDMO positioning.

Broad incumbents

• Thermo Fisher Scientific (Patheon): Global CDMO offering a broad portfolio including sterile injectables, lyophilization, and oral solids across hundreds of customers — comparable services but at vastly greater scale, breadth, and global footprint than ANFARM.

Regional players

• Helm AG: German-based pharmaceutical manufacturer and distribution company with focus on generics, licensing, and global markets — comparable in the licensing/3rd party manufacturing distribution model serving international markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anfarm